ClinicalTrials.gg
RecruitingNCT07255144Updated Nov 28, 2025

Ultrafast Ultrasound Imaging in Pediatric Cardiology

An observational study in CHD - Congenital Heart Disease, sponsored by University Hospital, Bordeaux. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by University Hospital, Bordeaux · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
300
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 73 studies in Heart Defects, Congenital with a site in France — 19 open to participants now, 22 under way, none of them phase 3. Heart Defects, Congenital · France.

Planned enrollment
16th of 39
300 · median 300
Started
2025
with 9 others
Observational
39 of 73
8 open now
Primary completion
2028-03
later than 15 of 21 live
Registered
69th of 73
by date
Lead sponsor
7 of 73
University Hospital, Bordeaux

Among the 73 studies in Heart Defects, Congenital with a site in France, this one is the 16th largest by planned enrollment of the 39 observational ones that give a count, is one of 10 that started in 2025, is one of 39 observational ones, reaches primary completion later than 15 of the 21 other live ones, and was the 69th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

19 of the 73 studies in Heart Defects, Congenital with a site in France are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Heart Defects, Congenital with a site in France, or all of them as a file.
02

Study summary

About 13 in 1000 children are born with heart disease. Current tools poorly assess heart filling in children, limiting treatment. This study explores ultrafast ultrasound imaging to measure heart stiffness and perfusion in children with congenital heart disease.

Read the detailed description

About 13/1000 children are born with heart disease. As a result of better treatment, there is an increasing population of children surviving with congenital heart disease (CHD) as well as a growing number of children with obesity, hypertension and serious chronic diseases, such as cancer and kidney disease, who are at risk of developing heart disease. All of these diseases affect the heart muscle and one of the main mechanisms resulting in heart muscle damage is the development of scar tissue (fibrosis). Fibrosis makes the heart muscle stiffer and therefore more difficult to fill. The heart must fill properly with blood in order to function well; but it is very difficult to study the filling of the heart using current diagnostic tools. One of the main challenges in pediatric cardiology is that non-invasive diagnostic approaches used in adult patients to assess heart filling (diastolic function) have proven inadequate in children. This knowledge gap has limited therapeutic progress in this vulnerable population; and to date there is no effective therapy that improves the filling of the heart.

The aim of this study is to explore new potential of ultrasound to assess diastolic function in CHD children. Ultrafast ultrasound imaging (UFUS), consisting of ultrasound images at a very high rate, is a new ultrasound approach to assess cardiac function.

Using a Verasonics system (ultrasound open platform), we will assess the myocardial stiffness and the myocardial perfusion by UFUS.

03

Conditions studied

  • CHD - Congenital Heart Disease

Keywords

  • Congenital heart disease
  • Paediatric
  • Cardiac Imaging
  • Ultrafast ultrasounf
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Every patient of CHD department of any age or any sex: 300 participants including 100 general population patients and 200 patients with CHD

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Every patient of CHD department of any age or any sex:

    • Patients with CHD
    • General population patients in good general health as evidenced by medical history coming to our department for a check-up OR diagnosed with small Atrial Septal Defect or small Patent Foramen Ovale
  • Social security affiliation
  • Parental or legal guardian's non-opposition

Exclusion criteria

Exclusion Criteria:

  • Arrhythmia
  • Segmental kinetic disorder.
  • Pacemaker or multisite stimulation, defibrillator,
  • Anechoic
  • Allergy to echocardiography gel.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • CHD

    Patients with CHD

    Other: Cardiac Ultrafast Ultrasound

  • General population

    General population patients in good general health as evidenced by medical history coming to our department for a check-up OR diagnosed with small Atrial Septal Defect or small Patent Foramen Ovale

    Other: Cardiac Ultrafast Ultrasound

Interventions

  • OtherCardiac Ultrafast Ultrasound

    Ultrafast ultrasound imaging(UFUS), ultrasound images at a very high rate, using a Verasonics system (ultrasound open platform).

06

What researchers measure

Primary outcomes

  1. Myocardial stiffness

    assessed with ultrasound data processed using the Verasonics system, to evaluate diastolic function

    Time frame: Baseline

  2. Myocardial perfusion

    assessed with ultrasound data processed using the Verasonics system, to evaluate diastolic function

    Time frame: Baseline

Secondary outcomes

  1. Echocardiographic parameters

    3\. Echocardiographic parameters according to international guidelines for screening for structural or functional intra-cardiac abnormalities (Lopez et al. JASE. 2024) and assessed by conventional ultrasound and ultrafast ultrasound.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2028, 36 months after the start.

Of 178 non-industry observational studies under Heart Defects, Congenital, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 83. This study's planned 36 months is below that.

Counting every sponsor, half of 185 studies reached it within 44 months; a quarter within 17 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Nov 28, 2025
StartActual
Mar 11, 2025
Primary completionEst.
Mar 11, 2028
CompletionEst.
Mar 11, 2028
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07255144
Responsible party
Sponsor
First posted
Nov 28, 2025
Start date
Mar 11, 2025
Primary completion
Mar 11, 2028 (estimated)
Completion
Mar 11, 2028 (estimated)
Last update
Nov 28, 2025

Study contacts

Olivier VILLEMAIN, MD, PhD
Contact
olivier.villemain@chu-bordeaux.fr
+33 5 24 54 94 79 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion